| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
|
| 药代性质 (ADME/PK) |
Absorption, Distribution and Excretion
Following oral administration of 14C dimethyl phthalate to rats or mice, radioactivity was detected in blood and various tissues. Peak radioactivity was reached within 1 hour. The highest radioactivity was observed in the kidneys, followed by the liver, fat, and spleen. After 24 hours, 91% of the administered dose was excreted in the urine and 4.1% in the feces. A series of phthalate esters, including dimethyl phthalate, diethyl phthalate, dibutyl phthalate, and di(2-ethylhexyl) phthalate, were subjected to transdermal absorption assays using human and rat epidermal membranes mounted in a glass diffusion cell. These esters were applied directly to the epidermal membrane. After application, each phthalate exhibited a hysteresis phase followed by a linear absorption phase. For all four phthalates, human skin permeability was lower than that in rat skin. Larger molecular weights appear to correlate with longer hysteresis times, but this relationship is not always valid. Phthalate esters exhibit water solubility ranging up to 300 times and a wide range of lipophilicity. Skin permeability increases slightly upon contact with the human epidermis. Post-exposure, epidermal membrane permeability undergoes relatively significant changes. This study investigated the absorption of a range of phthalates on rat skin. The phthalates tested included: dimethyl phthalate, diethyl phthalate, dibutyl phthalate, diisobutyl phthalate, dihexyl phthalate, di(2-ethylhexyl) phthalate, diisodecyl phthalate, and benzylbutyl phthalate. A 1.3 cm diameter skin patch was taken from the back of male F344 rats, shaved, and 14(C) phthalate was applied at a dose of 157 μmol/kg. The applied area was then covered with a perforated cap. Rats were restrained and housed in metabolic cages for 7 days to collect urine and feces. Urine and feces were collected every 24 hours, and the amount of 14(C) excreted was used as an indicator of transdermal absorption. At 24 hours, diethyl phthalate (DIP) had the highest excretion rate (26%). The amount of 14(C) excreted in the first 24 hours decreased significantly with increasing alkyl side chain length. The highest percentage of cumulative excreted dose over 7 days was observed for DEP, DIB, and DIB, approximately 50-60% of the applied 14(C) dose. The absorption rates of DEP, DIB, and DIB were between these two (20-40%). Except for DIB, the primary route of excretion for all phthalate esters was urine. DIB had extremely low absorption and was almost entirely excreted in urine. Seven days later, the residual dose percentage of each phthalate in the body was extremely low, and no specific tissue distribution was observed. Most of the unexcreted dose remained at the administration site. These data suggest that the structure of the phthalates determines the extent of their transdermal absorption. Diethyl phthalate (DMP) had the highest absorption rate, which subsequently decreased significantly with increasing alkyl side chain length. DMP is readily absorbed from the skin, intestine, peritoneum, and lungs. For more complete data on the absorption, distribution, and excretion of the six dimethyl phthalates, please visit the HSDB record page. Metabolites/Metabolites: Intestinal extracts from humans, ferrets, and baboons, as well as liver extracts from the latter two animals, can break down dimethyl phthalate into monoesters. In vitro studies on the metabolism of dimethyl phthalate, dibutyl phthalate, di-n-octyl phthalate, and diethyl phthalate in rat liver and kidney homogenates showed that the lower the molecular weight of the phthalate, the faster the metabolic rate. Compared with liver homogenate, rat kidney homogenate showed a relatively slower degradation rate of esters. After a single oral gavage of 120 mg of dimethyl phthalate to rats via gastric tube, 44.6% of dimethyl phthalate was detected in the urine, of which 77.5% was monomethyl phthalate, 14.4% was phthalic acid, and 8.1% was intact dimethyl phthalate. …In host-mediated mutagenesis experiments, rats were intraperitoneally injected with dimethyl phthalate (DMP) (2 g/kg body weight); 24-hour urine was collected, and… phthalic acid-containing derivatives were extracted and analyzed. The extracted urine contained phthalic acid equivalent to 1.96 mg/mL of urine. Over 97% of the phthalic acid-containing derivatives in the extracted urine were non-mutagenic metabolites of DMP—methyl phthalate (MMP). In vitro experiments showed that rat liver homogenate hydrolyzed 93% of carbonyl-labeled (14)C-DMP (7.7 mM) to MMP within 2 hours, binding 0.07 nmol of (14)C phthalate/mg liver macromolecule. In contrast, rat epidermal homogenate metabolized only 5% of carbonyl-labeled (14)C-DMP, but its binding level was 38 times higher (2.66 nmol/mg macromolecule), and no binding to nucleic acids was detected. Compared to the skin and plasma, the liver exhibited a 5-fold higher DMP monoesterase activity (1240 nmol/hr/mg protein), and a 67% inhibition of this enzyme activity resulted in a 4.4-fold increase in the number of phthalate-bound macromolecules in the liver (0.31 nmol vs. 0.07 nmol carbonyl-labeled (14)C-DMP/mg macromolecule). In addition to MMP, DMP metabolism in the liver also produces formaldehyde. When ethanol was used to inhibit the oxidation of DMP-derived methanol from liver homogenate, formaldehyde accumulation was reduced by 74%, and the binding of methyl-labeled (14)C-DMP to nucleic acids and macromolecules was reduced by 71% and 73%, respectively. (Unlike carbonyl-labeled (14)C-DMP, methyl-labeled (14)C-DMP hydrolyzes to (14)C-labeled methanol.) These results indicate that DMP diesters…can bind to other macromolecules in the skin and liver, in addition to nucleic acids. Although DMP is rapidly metabolized in the liver to monoesters (MMPs) and methanol, thus preventing elevated phthalate binding levels and DMP-induced bacterial mutations, it also oxidizes DMP-derived methanol to formaldehyde, a metabolite capable of binding to macromolecules, including nucleic acids. For more complete data on the metabolism/metabolites of dimethyl phthalates (12 in total), please visit the HSDB record page. Phthalate esters are first hydrolyzed to monoester derivatives. Once formed, these derivatives can be further hydrolyzed in the body to phthalic acid or conjugated with glucuronic acid, both of which are excreted. The terminal or penultimate carbon atom of the monoester can also be oxidized to an alcohol, which can be excreted directly or first oxidized to an aldehyde, ketone, or carboxylic acid. Monoesters and their oxidized metabolites are excreted in urine and feces. (A2884) |
|---|---|
| 毒性/毒理 (Toxicokinetics/TK) |
Toxicity Summary
Identification and Uses: Dimethyl phthalate (DMP) is a pale yellow or colorless oily liquid (solid below 42°F) with a slightly aromatic odor. It is used as a plasticizer in nitrocellulose and cellulose acetate resins, and as a component in solid rocket propellants, varnishes, plastics, rubber, coatings, safety glass, and molding powders. In the past, it has been used as a fly repellent and leech repellent for horses and cattle. DMP is not currently registered for use in the United States, but approved pesticide uses may change periodically; therefore, it is essential to consult federal, state, and local authorities for current approved uses. Human Exposure and Toxicity: In humans, dimethyl phthalate can cause skin irritation and, in one individual, induce anaphylaxis. Repeated inhalation of its vapors can irritate the nasal cavity and upper respiratory tract. Ingestion of dimethyl phthalate (DMP) may cause stomach irritation, dizziness, and coma. In a fatal case of suicidal ingestion of a mixture containing dimethyl phthalate and ketone peroxides, the primary symptoms of poisoning were marked esophagitis, gastritis, and bleeding. After 18 hours of in vitro culture containing 0.4 mM DMP, the in vitro mortality rate of human sperm decreased by 25%. DMP did not cause chromosomal damage in human leukocytes. DMP is not a known human carcinogen. Animal studies: Repeated application of DMP to the skin of mice caused irritation and ulceration, but produced only mild skin and ocular toxicity in rabbits. Acute oral and dermal toxicity was low in several animals. Oral studies in rats showed that repeated exposure to DMP may lead to kidney damage and mild liver damage. Repeated skin contact with DMP in rabbits resulted in kidney and liver damage. Inhalation of DMP at a concentration of 250 ppm caused severe mucosal irritation in cats; at a concentration of 1250 ppm, animals exhibited lethargy. In mice, inhalation of 0.7–1.8 mg/m³ DMP (4 hours daily) for 4 months resulted in changes in respiratory rate, neurological function, liver and kidney function, and blood morphology. Feeding rats with a diet containing 2% dimethyl phthalate for one week significantly reduced testosterone levels in the testes and serum, as well as serum dihydrotestosterone levels. Offspring of mice and rats administered DMP orally or dermatologically developed normally, while intraperitoneal injection of DMP in pregnant rats resulted in fetal death and malformations. Repeated application of DMP to the skin of mice did not increase the tumorigenicity of known skin carcinogens. Mutagenic activity of DMP was observed in Salmonella typhimurium (Ames test). Signs of chromosomal damage appeared in hepatocytes of rats with repeated dermal DMP application, but this was not observed in bone marrow cells of mice with a single DMP injection. In cultured Chinese hamster ovary cells, DMP induced sister chromatid exchange only upon metabolic activation. DMP did not induce chromosomal aberrations in cultured Chinese hamster ovary cells regardless of metabolic activation. Therefore, DMP is mutagenic only after metabolism in certain in vitro studies. This may be due to the formation of active substances such as formaldehyde. Since DMP is not mutagenic in vivo, any active metabolites appear to be rapidly detoxified. Ecotoxicity study: 100 ppm DMP showed acute toxicity to larvae of Palaemonetes pugio (grass shrimp). A concentration of 100 ppm DMP significantly prolonged the time required for larval development to the first larval stage. This study investigated the bioavailability of phthalate compounds, including dimethyl phthalate (DMP), in earthworms (Eisenia fetida). Earthworms were exposed to two artificially contaminated farmland and forest soils. The results showed that phthalates were not detected in the earthworms. Phthalate compounds are endocrine disruptors. They reduce testosterone production in the fetal testes and inhibit the expression of steroid-producing genes by reducing mRNA expression. Some phthalate compounds have also been shown to reduce the expression of insulin-like peptide-3 (insl3). insl3 is an important hormone secreted by interstitial cells of the testes and is crucial for the development of the gubernaculum testis. Animal studies have shown that these effects can disrupt reproductive development and may lead to various malformations in affected offspring. (A2883) Toxicity Data LCLo (cat) = 9,630 mg/m3/6H LD50: 6800 mg/kg (oral, rat) (T13) LD50: 3375 mg/kg (intraperitoneal, rat) (T13) LD50: 38000 mg/kg (dermal, rat) (L1332) LD50: 324 mg/kg (intravenous, rat) (L1332) Interactions ……Mice were sensitized percutaneously with fluorescein isothiocyanate (FITC) dissolved in acetone containing phthalates. Sensitization was assessed by ear swelling after FITC stimulation. Drained lymph node cells were collected 24 hours after skin sensitization, and FITC fluorescence was detected by flow cytometry. FITC-positive cells were identified by three-color flow cytometry using anti-CD11c and anti-CD11b antibodies. ... When mice were sensitized with FITC in acetone solution containing dibutyl phthalate (DBP) or di-n-propyl phthalate (DPP), a significantly enhanced ear swelling response was observed. Dimethyl phthalate (DMP) and diethyl phthalate (DEP) had weaker effects, but still produced some enhancement. ... Non-human toxicity values Oral LD50 in rats: 6800 mg/kg Oral LD50 in rats: 2860 mg/kg Intraperitoneal LD50 in rats: 3375 mg/kg Dermal LD50 in rats: 38000 mg/kg For more complete non-human toxicity data on dimethyl phthalate (out of 13), please visit the HSDB record page. |
| 参考文献 | |
| 其他信息 |
Dimethyl phthalate (DMT) is a water-white liquid with no noticeable odor. It is denser than water, insoluble in water, and therefore sinks. Its flash point is 300°F (149°C). Contact with eyes may cause severe irritation, and direct skin contact may cause mild irritation. It is used in the manufacture of a variety of products, including plastics, insect repellents, safety glass, and varnish coatings. DMT is a phthalate, diester, and methyl phthalate. DMT has a wide range of uses, including in solid rocket propellants, plastics, and insect repellents. Acute (short-term) exposure to DMT via inhalation in humans and animals can cause irritation to the eyes, nose, and throat. There is currently no information on the chronic (long-term), reproductive, developmental, or carcinogenic effects of DMT in humans. Animal studies suggest that long-term oral ingestion of this chemical may have mild effects on growth and kidneys. The U.S. Environmental Protection Agency (EPA) has classified DMT as a Group D substance, meaning its carcinogenicity in humans cannot be determined. Dimethyl phthalate (DMT) has been reported to be found in scallions (Allium ampeloprasum), the Canadian larva (Cryptotaenia canadensis), and other organisms with relevant data. DMT is a phthalate ester. Phthalate esters are esters of phthalic acid, primarily used as plasticizers, mainly for softening polyvinyl chloride (PVC). They are found in a wide variety of products, including adhesives, building materials, personal care products, detergents and surfactants, packaging materials, children's toys, paints, pharmaceuticals, food, and textiles. Phthalate esters have endocrine-disrupting effects and are therefore harmful. Due to these health concerns, the United States and the European Union are phasing out phthalates from many products. (L1903)
|
| 分子式 |
C10H10O4
|
|---|---|
| 分子量 |
194.19
|
| 精确质量 |
194.057
|
| CAS号 |
131-11-3
|
| 相关CAS号 |
Dimethyl phthalate (Ring-d4);93951-89-4;Dimethyl phthalate-d6;85448-30-2
|
| PubChem CID |
8554
|
| 外观&性状 |
Colorless to light yellow liquid
|
| 密度 |
1.2±0.1 g/cm3
|
| 沸点 |
282.7±8.0 °C at 760 mmHg
|
| 熔点 |
2 °C(lit.)
|
| 闪点 |
146.1±0.0 °C
|
| 蒸汽压 |
0.0±0.6 mmHg at 25°C
|
| 折射率 |
1.515
|
| LogP |
1.64
|
| tPSA |
52.6
|
| 氢键供体(HBD)数目 |
0
|
| 氢键受体(HBA)数目 |
4
|
| 可旋转键数目(RBC) |
4
|
| 重原子数目 |
14
|
| 分子复杂度/Complexity |
200
|
| 定义原子立体中心数目 |
0
|
| SMILES |
O=C(OC)C1=CC=CC=C1C(OC)=O
|
| InChi Key |
NIQCNGHVCWTJSM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H10O4/c1-13-9(11)7-5-3-4-6-8(7)10(12)14-2/h3-6H,1-2H3
|
| 化学名 |
dimethyl benzene-1,2-dicarboxylate
|
| 别名 |
NSC-15398; NSC 15398; Dimethyl phthalate
|
| HS Tariff Code |
2934.99.9001
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意: 本产品在运输和储存过程中需避光。 |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
DMSO : ~100 mg/mL (~514.99 mM)
|
|---|---|
| 溶解度 (体内实验) |
配方 1 中的溶解度: ≥ 2.5 mg/mL (12.87 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 配方 2 中的溶解度: ≥ 2.5 mg/mL (12.87 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 例如,若需制备1 mL的工作液,可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。 *20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。 View More
配方 3 中的溶解度: ≥ 2.5 mg/mL (12.87 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1496 mL | 25.7480 mL | 51.4960 mL | |
| 5 mM | 1.0299 mL | 5.1496 mL | 10.2992 mL | |
| 10 mM | 0.5150 mL | 2.5748 mL | 5.1496 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。